<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>34(8)</volume><submitter>Lim LL</submitter><funding>Merck Sharp &amp;amp; Dohme and Takeda</funding><funding>Eli Lilly</funding><funding>Impeto Medical to the Asia Diabetes Foundation (ADF)</funding><funding>Boehringer Ingelheim</funding><funding>Bayer</funding><funding>AstraZeneca</funding><funding>Chinese University of Hong Kong Foundation</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Early detection and risk factor control prevent chronic kidney disease (CKD) progression. Evaluation of peripheral autonomic dysfunction may detect incident cardiovascular-renal events in type 2 diabetes (T2D).&lt;h4>Methods&lt;/h4>SUDOSCAN, a non-invasive tool, provides an age-adjusted electrochemical skin conductance (ESC) composite score incorporating hands/feet ESC measurements, with a score ≤53 indicating sudomotor dysfunction. A consecutive cohort of 2833 Chinese adults underwent structured diabetes assessment in 2012-13; 2028 participants without preexisting cardiovascular disease (CVD) and CKD were monitored for incident cardiovascular-renal events until 2015.&lt;h4>Results&lt;/h4>In this prospective cohort {mean age 57.0 [standard deviation (SD) 10.0] years; median T2D duration 7.0 [interquartile range (IQR) 3.0-13.0] years; 56.1% men; 72.5% never-smokers; baseline ESC composite score 60.7 (SD 14.5)}, 163 (8.0%) and 25 (1.2%) participants developed incident CKD and CVD, respectively, after 2.3 years of follow-up. The adjusted hazard ratios (aHRs) per 1-unit decrease in the ESC composite score for incident CKD, CVD and all-cause death were 1.02 [95% confidence interval (CI) 1.01-1.04], 1.04 (1.00-1.07) and 1.04 (1.00-1.08), respectively. Compared with participants with an ESC composite score >53, those with a score ≤53 had an aHR of 1.56 (95% CI 1.09-2.23) for CKD and 3.11 (95% CI 1.27-7.62) for CVD, independent of common risk markers. When added to clinical variables (sex and duration of diabetes), the ESC composite score improved discrimination of all outcomes with appropriate reclassification of CKD risk.&lt;h4>Conclusions&lt;/h4>A low ESC composite score independently predicts incident cardiovascular-renal events and death in T2D, which may improve the screening strategy for early intervention.</pubmed_abstract><journal>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</journal><pagination>1320-1328</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6680097</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Sudomotor dysfunction independently predicts incident cardiovascular-renal events and all-cause death in type 2 diabetes: the Joint Asia Diabetes Evaluation register.</pubmed_title><pmcid>PMC6680097</pmcid><pubmed_authors>Ma RCW</pubmed_authors><pubmed_authors>Ozaki R</pubmed_authors><pubmed_authors>Cheung KKT</pubmed_authors><pubmed_authors>Lim LL</pubmed_authors><pubmed_authors>Lau ESH</pubmed_authors><pubmed_authors>Kong APS</pubmed_authors><pubmed_authors>Chan JCN</pubmed_authors><pubmed_authors>Luk AOY</pubmed_authors><pubmed_authors>Fu AWC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sudomotor dysfunction independently predicts incident cardiovascular-renal events and all-cause death in type 2 diabetes: the Joint Asia Diabetes Evaluation register.</name><description>&lt;h4>Background&lt;/h4>Early detection and risk factor control prevent chronic kidney disease (CKD) progression. Evaluation of peripheral autonomic dysfunction may detect incident cardiovascular-renal events in type 2 diabetes (T2D).&lt;h4>Methods&lt;/h4>SUDOSCAN, a non-invasive tool, provides an age-adjusted electrochemical skin conductance (ESC) composite score incorporating hands/feet ESC measurements, with a score ≤53 indicating sudomotor dysfunction. A consecutive cohort of 2833 Chinese adults underwent structured diabetes assessment in 2012-13; 2028 participants without preexisting cardiovascular disease (CVD) and CKD were monitored for incident cardiovascular-renal events until 2015.&lt;h4>Results&lt;/h4>In this prospective cohort {mean age 57.0 [standard deviation (SD) 10.0] years; median T2D duration 7.0 [interquartile range (IQR) 3.0-13.0] years; 56.1% men; 72.5% never-smokers; baseline ESC composite score 60.7 (SD 14.5)}, 163 (8.0%) and 25 (1.2%) participants developed incident CKD and CVD, respectively, after 2.3 years of follow-up. The adjusted hazard ratios (aHRs) per 1-unit decrease in the ESC composite score for incident CKD, CVD and all-cause death were 1.02 [95% confidence interval (CI) 1.01-1.04], 1.04 (1.00-1.07) and 1.04 (1.00-1.08), respectively. Compared with participants with an ESC composite score >53, those with a score ≤53 had an aHR of 1.56 (95% CI 1.09-2.23) for CKD and 3.11 (95% CI 1.27-7.62) for CVD, independent of common risk markers. When added to clinical variables (sex and duration of diabetes), the ESC composite score improved discrimination of all outcomes with appropriate reclassification of CKD risk.&lt;h4>Conclusions&lt;/h4>A low ESC composite score independently predicts incident cardiovascular-renal events and death in T2D, which may improve the screening strategy for early intervention.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Aug</publication><modification>2024-11-13T08:07:29.597Z</modification><creation>2019-08-12T07:06:33Z</creation></dates><accession>S-EPMC6680097</accession><cross_references><pubmed>29939305</pubmed><doi>10.1093/ndt/gfy154</doi></cross_references></HashMap>